Overview

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

---

Investment Highlights

---

Profile

Cord Blood America is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in future stem cell therapy. For an initial fee of approx. $1,950 and an annual storage fee of approx. $125 for each year thereafter, Co. provides the following services to each customer: Collection; Full-Time Physician and Customer Support; Transportation; Comprehensive Testing; and Cord Blood Preservation. At present, all of Co.'s cord blood units are tested, processed and stored at Bergen Community Regional Blood Center in Paramus, NJ.

There is uniformity in the belief that stem cells will play a key role in fighting disease as we move forward through this century. Some scientists are confident that stem cells will launch a new era in medicine, perhaps even curing some of our most intractable diseases. The umbilical cord which, at birth, traditionally has been thrown away, contains a rich store of stem cells. Cord Blood America, Inc., through its wholly owned subsidiaries, CorCell Companies Inc., and Cord Partners, Inc., markets a service to preserve the umbilical cord blood in a patented process for future use exclusively by the donating family. The collection takes less than five minutes, is painless, easy and non-invasive. Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. This list is guaranteed to grow as medical research learns more about the incredible healing power of stem cells.

You can't give birth to the same child twice. That is why marketing, and education, is such an important factor in this sector. Cord Blood America has assembled an experienced marketing team second to none in the industry. CBAI has nurtured deep relationships with healthcare insurance providers in key cities to drive the message to the parents when the insurance company is notified of that parent's pregnancy.

This is a growth industry: Only a few years ago, five percent of the four million women in the U.S. giving birth knew about preserving their umbilical cord blood and two percent of these took advantage of this life-saving procedure. The number of cord blood samples stored has since been growing by 50 percent a year, and more than four percent of all those giving birth now preserve the umbilical cord.  The Company already had revenues topping $5.89 million in 2007, the Company is well positioned for future growth as acceptance and knowledge about preserving umbilical cord continues to grow.

What Cord Blood America does not intend to do is to spend money on costly, endless research and development. Also, it does not need to discover something revolutionary… that’s been done already. The Company has certainly received some help from the U.S.'s top politician. On March 9th, 2009, an executive order was signed by President Obama eliminating restrictions on Federal funding of stem cell research which signalled a significant move forward for the entire stem cell sector.

"Scientists are confident that stem cell research will lead to fundamental improvements in the treatment of heart disease, diabetes, Parkinson's disease and other of our most difficult to treat illnesses," said Matthew Schissler, Cord Blood America Founder and CEO. "Stem cells are believed capable of becoming any tissue in the body, which could lead to treatments for illnesses currently impossible to cure," Mr. Schissler said.

The Company has reduced it's long term debt by over $2.5 Million in 2009 and is on track to become cash flow positive for the first time in its history when the Company files their quarterly numbers for the period ending June 30, 2009.

With the Company focusing strongly on becoming cash flow positive in '09 along with their aggressive expansion through internal growth coupled with strategic acquisitions and the new policy change done at the White House level, CBAI is a Company worth taking a closer look into as it strives to be the leader in educating about the advantages of these cord blood banking services and then to be the top performer in signing new families to utilize its services.

---

Products

Cord Blood America’s product is similar to an insurance policy, providing strong peace of mind. The preserved umbilical cord blood is saved specifically for the donating family. Besides current uses, medical research is ongoing on how to use these cells to combat heart disease, Parkinson’s disease, spinal cord injuries, sickle cell anemia, cancer and other difficult diseases to treat. Researchers postulate that the cells they remove from the umbilical cord blood can someday be turned into every single tissue in the body, making, for instance, the repair of a damaged heart possible, or facilitating recovery from a stroke by turning stem cells into brain cells. Cord blood has proven to contain the kind of stem cells that can be turned into red blood cells and disease-fighting white blood cells. They also totally avoid all the controversies involved with stem cells from other sources such as embryonic stem cells.

---

Growth Plan

• Build additional sales channels through obstetrics and gynecological practices and other healthcare professionals, hospitals and other health care influencers
• Continue to build insurance company alliances with, for example, Independence Blue Cross, AmeriHealth, Highmark, Mountain State Blue Cross Blue Shield, the National Labor Office of the Blue Cross Blue Shield Association and others -- to become a named ‘preferred provider’ for umbilical cord blood storage
• Expand market share in the U.S. and increase presence in the European market
• Acquisition roll-up of other profitable cord blood storage entities
• Continue organic growth through continued improvement of internal processes

---

Recent News and Press Releases

Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments
PR Newswire (Tue, May 19)

Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory
PR Newswire (Fri, May 15)

Cord Blood America Receives Commitment for $2.3 Million to Fund Its Own Stem Cell Laboratory
PR Newswire (Thu, May 14)

Cord Blood America to Acquire or Build Its Own Stem Cell Laboratory
PR Newswire (Thu, May 7)

CORD BLOOD AMERICA, INC. Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Tue, May 5)

Webcast Alert Update: CEO Interview Now Available
Business Wire (Thu, Apr 30)

CORD BLOOD AMERICA, INC. Financials
EDGAR Online Financials (Thu, Apr 30)

Cord Blood America Supports Effort in Congress to Inform on Value of Umbilical Cord Blood Stem Cell Storage
PR Newswire (Thu, Apr 30)
 

---

Management

MATT SCHISSLER, Founder, Chairman and CEO:

Mr. Schissler is a quintessential entrepreneur, with a track record of performance in founding companies, turning them into successes, opening markets and finding new business opportunities. Among these are Rainmakers International, Inc., an advertising agency. Mr. Schissler also held key management sales positions at the publicly traded TMP Worldwide, Inc., the former parent of Monster.com, where he pioneered a new business model allowing the company to increase revenues and profits. At that staffing firm, he managed more than 200 sales personnel.

STEPHANIE SCHISSLER, Founder and Consultant:

At Cord Partners, the wholly owned subsidiary, Ms. Schissler built, from the ground up, a customer oriented marketing program focused on providing the information and education necessary to allow parents to make this crucial decision.

JOE VICENTE, Vice President, Corporate Strategy:

Mr. Vicente has a long, successful history in assisting emerging growth companies, focusing on acquisitions, operational practices and efficiencies and sales management. He also served as Senior Vice President at TMP Worldwide, holding key strategic, operational and sales management positions.

---

Contact

Company Address:

501 Santa Monica Blvd., Suite 700, Santa Monica, CA 90401

Telephone: (310) 432-4090
Web Site: http://www.cordblood-america.com/

Investor Contact:

Paul Knopick, E & E Communications,
Phone: 949-707-5365
Email: pknopick@eandecommunications.com

---

FORWARD LOOKING STATEMENTS

This report includes forward-looking statements that reflect Cord Blood America, Inc. current expectations about its future results, performance, prospects and opportunities. Cord Blood America, Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause Cord Blood America, Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

---

Disclaimer

AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for Cord Blood America, Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2009 AllPennyStocks.com. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has not been compensated for its efforts in presenting the CBAI profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.